Tenofit EM Tablet contains Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg, a globally recommended fixed-dose antiretroviral combination used as a first-line therapy in the management of HIV-1 infection. This dual-action formulation works by inhibiting viral reverse transcriptase, effectively suppressing HIV replication and reducing viral load.
This combination is widely used as part of standard antiretroviral therapy regimens and is also approved for HIV pre-exposure prophylaxis (PrEP). Its proven efficacy, favorable resistance profile, and once-daily dosing make it a preferred option in long-term HIV management programs.
For hospitals, ART centers, and institutional suppliers, Tenofit EM Tablet is a high-demand antiretroviral medicine, consistently required for government HIV programs, private infectious disease clinics, and specialty care hospitals. Ongoing treatment protocols ensure continuous procurement and stable market movement.
Adding Tenofit EM Tablet to your portfolio strengthens your HIV and antiretroviral therapy segment, enabling opportunities in hospital supply, national health tenders, export markets, and third-party manufacturing. Its essential role in HIV treatment and prevention makes it a strategically important and commercially valuable product for pharmaceutical distributors.